South-East Asia Bioprocessing (SEA) Market Report features survey-based data analysis of Biopharma market in South-East Asia Region. The report covers competitive insights from top Biopharma, Biotech, Academic Institutes, and Contract Manufacturing Organizations (CMOs) involved in the development and manufacturing of large molecules such as Monoclonal Antibodies, Recombinant Proteins, Cell Therapy, Bi-Specific Antibodies, Vaccines, and more.
The first section of the report covers comprehensive market analysis of the South-East Asia bioprocessing including market size and projected growth. It includes analysis and research-based insights on the Biopharma market growth, trends, drivers, and restraints within SEA region. This section has scope of biopharma growth and opportunities in SEA region in addition to insights into top partnerships and collaborations in the industry. It also provides country wise analysis of Thailand, Indonesia, Singapore, Vietnam and Malaysia to provide insights into the biologics market growth in the region. It includes detailed analysis of market share by country. Singapore holds the highest share in SEA Biopharma Market with 47%, followed by Thailand with 21%, Indonesia with 18%, Vietnam and Malaysia with 7%, respectively.
The second section covers competitive landscape of Biopharma/Biotech companies, Academic Institutes and CMOs including Siam Biosciences, Tcels, Bio-Net Asia, Government Pharmaceutical Organisation, Kingen Biotech, Queen Saovabha Memorial Institute from Thailand. Singapore based players included are SingCell, BTI, Cell Research Corporation, Tessa Therapeutics, Dot Bio, Travecta Therapeutics, Prestige Biopharma, Esco Aster, Lion TCR. Malaysian companies included are Malaysian Vaccine Pharmaceuticals and National Institutes of Biotechnology Malaysia. Also studies Indonesian Biopharma companies such as Biofarma, PT Kalbe Global Biomedika, Daewoong Infion, Bandung Institute of Technology and Vietnamese companies such as Nanogen Pharmaceutical Biotechnology, Vietnam Academy of Science and Technology and Vabiotech.
It studies company’s products, service offerings, future investment plans, technology adoption, decision making process and COVID-19 impact on organisations among many other parameters.
The third section of the report provides analysis of SEA biopharma market based on the survey conducted by IMAPAC with companies including Kingen Biotech, The Government Pharmaceutical Organisation, Vabiotech, Vitech Development Co, Ltd, Malaysian Vaccines & Pharmaceuticals, National Institutes of Biotechnology Malaysia, PT. Combiphar Donga, PT. Kalbio Global Medika, Biofarma, Bandung Institute of Technology, Takeda, Cellvec, Bioprocessing Technology Institute. It reveals quantitative and qualitative findings to help Biopharma businesses understand technology solution providers and equipment suppliers in the SEA Market. It highlights the following parameters based on the questions covered in the survey
- Types of Biopharma Products Manufactured in SEA region
- Key Factors Influencing Supplier/Vendor Selection & Decision Making
- Competitive Landscape of Suppliers in SEA Region
- Customer Preferences of the Communication Channel
- COVID-19 Impact on Procurement Process and Regulations
- Future Plans of Biopharma, CMOs and Academic Institutes
This section also includes the list of respondents participated in the SEA Biopharma survey along with their responses.
The last section of the report features Sciex (Singapore).
The option to customize the report is available upon request to meet your data requirements for example any specific country or market data from SEA market. The customized report is comparatively cost-effective and dependent on data requirements.